A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 800-803

  Inoue, A ^a   Ishimoto, O ^b   Fukumoto, S ^c   Usui, K ^d   Suzuki, T ^e   Yokouchi, H ^f   Maemondo, M ^g   Kanbe, M ^h   Ogura, S ⁱ   Harada, T ^j   Oizumi, S ^k   Harada, M ^c   Sugawara, S ^b   Fukuhara, T ^a   Nukiwa, T ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b SENDAI KOUSEI HOSPITAL   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d Kanto Teishin Hospital   (Japan)

^e Isawa Hospital   (Japan)

^f Iwamizawa Rosai Hospital   (Japan)

^g Miyagi Cancer Center   (Japan)

^h Senseki Hospital   (Japan)

ⁱ SAPPORO CITY GENERAL HOSPITAL   (Japan)

^j Hokkaido Social Insurance Hospital   (Japan)

^k HOKKAIDO UNIVERSITY   (Japan)

more..

Author keywords

Amrubicin; Carboplatin; Chemotherapy; Elderly; Phase II study; Small cell lung cancer

Indexed keywords

AMRUBICIN; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DUODENUM ULCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HICCUP; HUMAN; INFECTION; JAPAN; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 77951952541     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp384     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Greenlee RT, Murray T, Boldenx S et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
3. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg SA (eds), Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams and Wilkins 2001; 983-1018.
4. Stephens RJ, Johnson DH. Treatment and outcomes for elderly patients with small cell lung cancer. Drugs Aging 2000; 17: 229-247.
5. Shepherd FA, Bezjak A. Treatment of small cell lung cancer in the elderly patients. In Pass HI, Mitchell JB, Johnson DH et al. (eds), Lung Cancer: Principles and Practice, 2nd edition. Philadelphia, PA: Lippincott Williams and Wilkins 2000; 1081-1091.
6. Okamoto H, Watanabe K, Nishiwaki Y et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999; 17: 3540-3545.
7. Okamoto H, Watanabe K, Kunikane H et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97: 162-169.
8. Yana T, Negoro S, Takada M et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007; 25: 253-258.
9. Ohe Y, Negoro S, Matsui K et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005; 16: 430-436.
10. Inoue A, Yamazaki K, Maemondo M et al. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. J Thorac Oncol 2006; 1: 551-555.
11. Sekine I, Yamamoto N, Kunitoh H et al. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 2004; 30: 359-368.
12. Jara C, Gómez-Aldaraví JL, Tirado R et al. Small-cell lung cancer in the elderly-is age of patient a relevant factor? Acta Oncol 1999; 38: 781-786.
13. Langer C, Manola J, Bernardo P et al. Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (Pts) receiving platinum (DDP)-based therapy (TX): implications of ECOG 5592. Proc Am Soc Clin Oncol 2000; 19: (Abstr 1912).
14. Oshita F, Kurata T, Kasai T et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 1995; 86: 1198-1202.
15. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
16. Hermes A, Bergman B, Bremnes R et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26: 4261-4267.